Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr;64(2):161-4.
doi: 10.1016/S0377-1237(08)80065-2. Epub 2011 Jul 21.

Dengue Vaccine: The Current Status

M S Mustafa  1 , V K Agrawal  2
Affiliations

Dengue Vaccine: The Current Status

M S Mustafa et al. Med J Armed Forces India. 2008 Apr.

Abstract

Dengue fever is a re-emerging public health problem with two-fifths of the world population being at risk of infection. Since there are no antiviral drugs available against the dengue virus, and vector control programmes have been largely unsuccessful in preventing outbreaks, vaccination seems to be the most viable option for preventing infection. An ideal dengue vaccine should provide long lasting immunity against all four serotypes of the virus. The envelope protein of the virus plays a key role in vaccine development. The present day candidate vaccines includes a live attenuated tetravalent vaccine, intertypic chimaeric vaccines based on live attenuated dengue virus vectors, chimaeric vaccines based on the live attenuated Yellow Fever 17D vector and recombinant vaccines which include vaccines based on flavivirus and non-flavivirus vectors. Tetravalent live attenuated vaccines, intertypic chimaeric vaccines and chimaeric vaccines are being tested in human trials. Recombinant DNA vaccines based on flavivirus and non-flavivirus vectors are being tested in animal trials. Recent studies have shown that the tetravalent formulations may elicit an unbalanced immune response. Research is continuing to find means of obtaining a balanced response to all antigens in the tetravalent formulations.

Keywords: Candidate vaccines; Clinical trials; Dengue fever.

PubMed Disclaimer

References

    1. Gubler DJ. Dengue and dengue haemorrhagic fever. Clin Microbiol Review. 1998;11:480–496. - PMC - PubMed
    1. Chaturvedi UC, Shrivastava R, Nagar R. Dengue vaccines: problems and prospects. Indian J Med Res. 2005;5:639–652. - PubMed
    1. Craig S, Thu HL, Lowry K. Diverse dengue Type 2 virus populations contain recombinant and both parental viruses in a single mosquito host. J Virol. 2003;77:4463–4467. - PMC - PubMed
    1. Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ. 2005;83:308–314. - PMC - PubMed
    1. Lancotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol. 1992;30:545–551. - PMC - PubMed

LinkOut - more resources